Gene-editing startup secures $56M to advance transposon-based cell therapies

Typewriter has raised $56 million to develop a gene-editing approach using transposable elements, which could enable the delivery of full genes into the body without viral vectors or CRISPR enzymes. The funding will support the company's work on in vivo CAR-T therapies, potentially simplifying how engineered immune cells are produced. This technology aims to overcome limitations of current gene delivery methods by leveraging naturally occurring genetic elements.

This funding round highlights a shift toward gene-editing methods that rely on naturally occurring genetic elements rather than viral vectors or CRISPR-based enzymes. Transposons, sometimes called “jumping genes,” can insert large DNA sequences into a cell’s genome, potentially allowing whole therapeutic genes to be delivered directly into a patient’s body. The company’s focus on in vivo CAR-T therapies suggests a future where engineered immune cells are produced inside the patient, rather than in a lab. That could reduce manufacturing complexity and shorten treatment timelines, though the approach remains early-stage.

The $56 million raise signals investor confidence in alternatives to established gene-delivery tools. Current methods often face hurdles such as immune responses, limited cargo capacity, or off-target effects. By leveraging transposable elements, the startup aims to address some of these constraints, though clinical validation is still needed. The funding will likely support preclinical studies and early trials, with the ultimate goal of simplifying cell therapy production.